Abstract
Polycystic Ovary Syndrome (PCOS) is the one of the common cause of menstrual irregularity in the United States and a leading cause of infertility. PCOS prevalence ranges from 6 to 10% in the United States. Because obesity may unmask PCOS, the incidence may increase as obesity rates increase. PCOS has been viewed as a collection of reproductive disorders, including polycystic ovaries, anovulation, infertility, and pregnancy loss, associated with hirsutism, acne, and obesity. More recently, PCOS has been linked with cardiovascular risk factors, such as elevated blood pressure, dyslipidemia, abnormal glucose metabolism, and coagulopathies. As many as one-third of PCOS women develop type 2 diabetes. Small observational studies have linked PCOS with early coronary artery disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zawedzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome (Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds.). Glasckwell Scientific, Boston, 1992; pp. 377–384.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1):19–25.
Balen A, Michelmore K. What is polycystic ovary syndrome? Hum Repro 2002; 17(9):2219–2227.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774–800.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovarian syndrome. J Clin Invest 1976;57:1320–1329.
Sherif K, Kushner H, Falkner BE. Sex hormone-binding globulin and insulin resistance in African-American women. Metab Clin Experim 1998;47(1):70–74.
Deaton MA, Glorioso JE, McLean DB. Congenital adrenal hyperplasia: not really a zebra. Amer Fam Physician 1999;59(5):1190–1196.
Luthold WW, Borges MF, Marcondes JA, Hakohyama M, Wajchenberg BL, Kirschner MA. Serum testosterone fractions in women: normal and abnormal clinical states. Metab Clin Exper 1993;42(5):638–643.
Sherif K. Benefits and risks of oral contraceptives. Amer J Obstet Gyn 1999;180(6):S343–S348.
Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gyn Endocrinol 1987;1:233–245.
Garber AJ, Duncan TJ, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Amer J Med 1997;103(6):491–497.
Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951.
Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews. 2001;(4):CD000194.
George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Human Repro 2003;18(2):299–304.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Sherif, K. (2008). Polycystic Ovary Syndrome. In: Clouse, A.L., Sherif, K. (eds) Women’s Health in Clinical Practice. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-469-8_10
Download citation
DOI: https://doi.org/10.1007/978-1-59745-469-8_10
Publisher Name: Humana Press
Print ISBN: 978-1-58829-631-3
Online ISBN: 978-1-59745-469-8
eBook Packages: MedicineMedicine (R0)